2026 European publication: modified GHK, Epitalon, Semax, Selank and Cortagen analogues — EP4758157A1
Filip Majewski · 2026 · EP4758157A1 · patent family 88092996
Published 2026-06-17.
Reported patent results
Reported findings
The disclosure reports cell-growth, telomerase-related and stability findings for chemically modified peptides, with several ambiguities in reporting.
Patent laboratory comparisons of modified versus parent peptides; no verified human treatment cohort.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| GHK-related long-term keratinocyte assay | Reported cell-number multiples versus control: GHK 260-fold, GHK-Cu 320-fold, Ac-GHK-Arg-NH2 360-fold | As stated in the patent; assay normalization and duration are insufficiently clear for clinical interpretation |
| Epithalon-related laboratory summary | 41.2% for modified peptide versus 33.3% for parent | The text combines telomerase activity and telomere elongation rather than clearly separating the endpoints |
| Cortagen-related Ki-67 | Approximately threefold expression-area increase for modified peptide versus more than twofold for parent at different stated concentrations | Different tested exposures prevent a simple potency ratio |
| Storage and chemical stability | Modified compounds described as more stable in comparison assays | Individual stability-table values not transcribed; no human half-life established |
In-vitro findings, unclear units and very large proliferation claims require independent verification. Modified analogues are not the parent peptides, and no human regeneration or longevity effect follows.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Modified analogue. The family claims chemically modified peptides, including acetylated parent sequences extended with C-terminal arginine amide; it also has a 2025 WO publication.
Ac-GHK-Arg-NH2 and the corresponding modified AEDG, Semax, Selank and Cortagen constructs are different molecules from their parents. The EP and WO publications are one family, not independent studies.
- Publication
- EP4758157A1 ↗ · 2026-06-17
- Earliest priority / filing
- 2023-08-13 / 2023-08-13
- Original applicant / assignee
- Individual
- Indexed status
- Pending · checked 2026-11-06
- Patent family
- 88092996 · family publications are related filings, not independent studies.
Original title, inventors and related publications
New peptides and use thereof
Inventors: Filip Majewski.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Ac-GHK-Arg-NH2 and the corresponding modified AEDG, Semax, Selank and Cortagen constructs are different molecules from their parents. The EP and WO publications are one family, not independent studies.
- In-vitro findings, unclear units and very large proliferation claims require independent verification. Modified analogues are not the parent peptides, and no human regeneration or longevity effect follows.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-88092996. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Filip Majewski. 2026 European publication: modified GHK, Epitalon, Semax, Selank and Cortagen analogues — EP4758157A1 EP4758157A1 · patent family 88092996 2026.
Molekul research summary: https://molekul.io/research/patent-ep4758157a1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
GHK-Cu & GHK family
A single research family collecting GHK-Cu, unbound GHK, Russian terminal extensions, stereochemical variants and related delivery constructs. The member map identifies which molecule each source actually studied; a shared card does not establish interchangeable biological activity.
Epitalon
Synthetic AEDG has direct human hormone and retinal findings. Long-term Epithalamin mortality studies concern the extract and are kept separate.
Semax
ACTH-fragment-derived peptide with clinical stroke and optic-nerve reports, healthy-volunteer imaging and preclinical neuroregulation research. Precursor, patent and dissertation sources remain separately labeled.
Selank
Tuftsin-derived peptide investigated in anxiety comparisons, stress models and neurochemical assays. Its clinical and laboratory evidence are kept distinct from unverified archival claims.
Cortagen
Listed in the 2013 short-peptide review under the authors’ proposed brain target. This historical label is not an established indication. Underlying studies need individual review.